Claims for Patent: 10,155,801

Summary for Patent: 10,155,801

Title:	Peptides and combination of peptides for use in immunotherapy against various tumors
Abstract:	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s):	Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Alchwald, DE), Schoor; Oliver (Tubingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Munchen Schwabing, DE), Stevermann; Lea (Tubingen, DE)
Assignee:	IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)
Application Number:	16/044,289
Patent Claims:	1. A method of treating a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize a tumor cell that aberrantly expresses a peptide/MHC complex on cell surface, wherein said peptide consists of the amino acid sequence of FLIENLLAA (SEQ ID NO: 67), wherein said cancer is selected from the group consisting of hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC). 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, wherein the population of activated T cells comprises CD8+ T cells. 6. The method of claim 1, wherein the MHC molecule is a MHC class I molecule. 7. The method of claim 1, wherein the activated T cells release a cytokine. 8. The method of claim 7, wherein the cytokine comprises interferon-gamma (IFN.gamma.). 9. The method of claim 1, wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cells. 10. The method of claim 9, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. 11. The method of claim 10, wherein the antigen presenting cell is a dendritic cell or a macrophage. 12. The method of claim 9, further comprising expanding the activated T cells in vitro. 13. The method of claim 12, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. 14. The method of claim 1, wherein the composition further comprises at least one adjuvant selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, particulate formulations with poly(lactid co-glycolid) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. 15. The method of claim 9, wherein the contacting is in vitro. 16. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T cells that selectively recognize a tumor cell that aberrantly expresses a peptide/MHC complex on cell surface, wherein said peptide consists of the amino acid sequence of FLIENLLAA (SEQ ID NO: 67), wherein said cancer is selected from the group consisting of hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), chronic lymphocytic leukemia (CLL), Merkel cell carcinoma (MCC), small cell lung cancer (SCLC), Non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC). 17. The method of claim 16, wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an WIC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cells. 18. The method of claim 17, wherein the contacting is in vitro. 19. The method of claim 16, wherein the immune response comprises cytotoxic T cell response. 20. The method of claim 16, wherein the population of activated T cells comprises CD8+ T cells.

Details for Patent 10,155,801

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2035-03-27